Current iron therapy in the light of regulation, intestinal microbiome, and toxicity: are we prescribing too much iron?
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic review methodology or new primary data
PubMed 38606523 · doi:10.1080/10408363.2024.2331477
What was done
This is a narrative review examining the causes and systemic consequences of iron deficiency, mechanisms of intestinal iron absorption and hepatic hepcidin regulation, and the comparative tolerability of standard versus low-dose oral iron therapy. The authors synthesize literature on how unabsorbed luminal iron alters the intestinal microbiome and impacts metabolic, immune, and gastrointestinal health.
What was found
The abstract reports no quantitative data, effect sizes, or participant numbers. Qualitatively, the review notes that standard oral iron regimens often cause gastrointestinal adverse effects and elevate hepatic hepcidin, which limits iron absorption. Excess unabsorbed iron promotes dysbiosis by favoring pathogenic bacteria and reducing protective species like bifidobacteria and lactobacilli. The authors state that low-dose iron therapy reduces hepcidin induction, maintains efficient absorption, replenishes iron stores, and causes significantly fewer side effects.
Why it matters
High-dose oral iron frequently fails due to adverse gastrointestinal events and poor adherence. Highlighting hepcidin kinetics and gut microbiome preservation provides a mechanistic rationale for shifting clinical practice toward lower-dose iron prescribing strategies.
Limits
The abstract provides no empirical data, statistical measures, or specific dosing definitions. As a narrative review, it lacks systematic search methodology, risk-of-bias assessments, and quantitative synthesis of primary trial outcomes.
Cited by
- supports Oral iron supplementation can nourish pathogenic bacteria and increase intestinal lipopolysaccharide (LPS) production.